Saliva test to predict premature births:
This article was originally published in Clinica
Biex's SalEst saliva test has obtained FDA marketing approval for use in predicting premature birth in third-trimester women. SalEst measures the level of the hormone estriol, which appears in saliva a few weeks before spontaneous pre-term labour occurs. The test, which will be available later this year, identifies the "vast majority" of affected women, says Dublin, California-based Biex, compared with the less than 50% accuracy of traditional risk scoring systems. It will be the company's first product.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.